Alzheimer's disease (AD) has been categorized by the Centers for Disease Control and 3 Prevention (CDC) as the 6 th leading cause of death in the United States. AD is a significant 4 health-care burden because of its increased occurrence (specifically in the elderly population) 5 and the lack of effective treatments and preventive methods. With an increase in life expectancy, 6 the CDC expects AD cases to rise to 15 million by 2060. Aging has been previously associated 7 with susceptibility to AD, and there are ongoing efforts to effectively differentiate between normal 8 and AD age-related brain degeneration and memory loss. AD targets neuronal function and can 9 cause neuronal loss due to the buildup of amyloid-beta plaques and intracellular neurofibrillary 10 tangles.
(PCA) plots to visualize the variability in the data and the effectiveness of possible batch effect removal 139 (Irizarry and Love, 2015). 141 We modeled the merged expression data (see model breakdown below) prior to running analysis of 142 variance (ANOVA) to analyze differences among the different study factors ( Figure 1D ) (Pavlidis, 2003) . 143 We defined age group, sex, disease state, study and tissue as factors. 144 x ∼ i x i + i,j;j>i We selected the TukeyHSD results from the disease status factor, and focused on the "Control-AD" 171 pairwise comparison to assess statistically significant gene expression differences. To assess biological 172 effect, and select an appropriate fold-change-like cutoff (as our results had already been transformed 173 using a Box-Cox transformation), we calculated the quantiles based on the TukeyHSD difference of 174 mean difference values (Supplemental Table 1 ). We used a two-tailed 10% and 90% quantile to identify 175 significantly up and down regulated genes ( Supplemental Table 1 ).
140

Linear Model Analysis and Analysis of Variance
x i : x j(1)
176
The differentially expressed genes (DEG) by disease status factor were subsequently used to determine 177 whether or not there was a sex, age or tissue effect on them. For sex, we used the DEG to filter the 178 TukeyHSD results for sex factor differences, identified statistically significant sex-relevant genes based on 179 p-value cutoff, and again computed the 10% and 90% quantile based on the difference of means between 180 male and female groups. We repeated the above steps for age group, but focused only on the binary 181 comparisons where all age groups were compared to the <60 age group, which was used as a baseline 182 (i.e. computed the mean gene expression differences per group comparison, i-< 60, where i stands for any 183 age group). This was carried out to enable us to compare the progression with age, relative to a common 184 reference across all age groups. As for tissue, we carried out the same steps as above to determined DEG 185 based on comparisons both a hippocampus-based baseline, as well a blood-based baseline.
186
Following the identification of the DEG by disease status and sex, we visualized the raw expression data 187 for these genes in heatmaps. In addition to this, we generated heatmaps using the difference of means 188 values for the significantly different age group and tissue genes. 
RESULTS
With our data selection criteria outlined in Figure 1B we identified 8 datasets from GEO and Array Express 196 to conduct our meta-analysis to assess differences in gene expression due to disease state, sex, age and 197 tissue ( Table 1) . We merged the processed expression data by common gene names, which gave us a total 198 of 2,088 samples and 16,257 genes. The 2,088 samples consisted of 771 healthy controls, 868 AD subjects, 199 449 subjects reported as possibly having AD, 1308 females and 780 males.
200
ComBat Batch Effect Correction
201
Combining data from different platforms, tissues and different laboratories introduces batch effects.
202
Batch effects are sources of non-biological variations that can affect conclusions. We used ComBat in 203 R which works by adjusting the data based on a known batch effect. For our analysis we classified the 204 study variable as our batch (and also the study and type of platform are directly related). We used PCA to 205 visualize variation in the merged expression data before and after ComBat. In Figure 2 before correcting 206 for batch effects, the datasets separate into 4 main clusters with a variance of 54.3% in PC1 and 13% in 207 PC2. Following ComBat, those main clusters appear to be removed, with an overall reduction in variation 208 for both principal components. We also looked at how the data separated by factor. In Figure 2B , there are 209 two clear groups and this separation is accounted for when we look at the separation in the data by tissue confirmed the need to include the study as a factor in the linear model analysis. 3). In addition to synapses and neurodegeneration, the long term potentiation (23 gene hits) pathway was enriched genes in the KEGG AD pathway, we used the TukeyHSD results to determine whether genes 233 were up-or down-regulated (see ST7 of online supplemental data). To further assess the 73 gene hits 234 identified in the enriched AD pathway we computed their mean differences between the AD and control, (Figure 4) .
214
Analysis of Variance on Gene Expression By Disease
239
Up and Down-Regulated Gene Expression in AD and Sex Specific Differences 240 We conducted a post-hoc analysis (TukeyHSD) on the 3,735 statistically significant disease genes to 241 identify level differences and explore up-and down-regulation of genes. We were particularly interested in 242 the control compared to AD gene expression differences, and how these could be further sub-categorized 243 to explore effects by sex, age and tissue. We used a Bonferroni adjusted p-value cut off for significance 244 (<0.000013) and the 10% two-tailed quantile to determine significantly up and down regulated genes 245 (Supplemental Table 1 ). In the Control-AD TukeyHSD comparisons, genes were classified as up-regulated Figure 9 . Heatmap with gene clustering to visualize tissue effect (difference in means) on the differentially expressed disease (control-AD) gene list.
